Burnet Institute Lands $4 Million from GuoMinXinHe Investment Fund

Burnet Institute of Melbourne, Australia has finalized a $4 million investment from GuoMinXinHe, a Beijing investment firm, to underwrite operations of its China subsidiary, Nanjing BioPoint Diagnostic Technology Ltd. BioPoint is tasked with China development of a low-cost point-of-care assay for liver function. After the investment, Burnet and GuoMinXinHe will own Nanjing BioPoint jointly. More details.... Share this with colleagues: // //